Showing results (31-40 of 67) with videos related to
Sort By:
Pageof 7
Advanced Materials (Deerfield Beach, Fla.)|March 4, 2020
Necroptosis-Inducible Polymeric Nanobubbles for Enhanced Cancer SonoimmunotherapyWooram Um, Hyewon Ko, Dong Gil You, et al.Biomaterials Research|May 2, 2024
Accurately Controlled Tumor Temperature with Silica-Coated Gold Nanorods for Optimal Immune Checkpoint Blockade TherapyWan Su Yun, Wonseok Yang, Man Kyu Shim, et al.Theranostics|March 10, 2022
Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell deathYujeong Moon, Man Kyu Shim, Jiwoong Choi, et al.Advanced Materials (Deerfield Beach, Fla.)|June 20, 2024
Light-Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer ImmunotherapyJiwoong Choi, Byeongmin Park, Jung Yeon Park, et al.ACS Nano|June 24, 2021
Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer ImmunotherapyJiwoong Choi, Man Kyu Shim, Suah Yang, et al.Bioconjugate Chemistry|May 6, 2020
In Situ One-Step Fluorescence Labeling Strategy of Exosomes via Bioorthogonal Click Chemistry for Real-Time Exosome Tracking In Vitro and In VivoSukyung Song, Man Kyu Shim, Seungho Lim, et al.Journal of Nanobiotechnology|March 14, 2024
Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapyJinseong Kim, Man Kyu Shim, Yujeong Moon, et al.Journal of Controlled Release : Official Journal of the Controlled Release Society|September 1, 2020
Epidermal growth factor (EGF)-based activatable probe for predicting therapeutic outcome of an EGF-based doxorubicin prodrugHan Young Kim, Sang Hoon Um, Yejin Sung, et al.Angewandte Chemie (International Ed. in English)|November 21, 2024
Self-Assembled Peptide-Derived Proteolysis-Targeting Chimera (PROTAC) Nanoparticles for Tumor-Targeted and Durable PD-L1 Degradation in Cancer ImmunotherapyYujeong Moon, Hanhee Cho, Jinseong Kim, et al.Biomaterials|October 7, 2022
Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunitySuah Yang, Man Kyu Shim, Sukyung Song, et al.Pageof 7